SFDA Saudi Arabia Medical Device Registration

Medical devices and in vitro diagnostics in Saudi Arabia are regulated by the Saudi Food and Drug Authority (SFDA). SFDA oversees establishment licensing, authorized representatives, product marketing authorization, importation, and post-market controls. Manufacturers should confirm the current requirements in the official SFDA medical device regulations and guidance before filing.

Saudi medical device classification

Saudi Arabia uses risk Classes A, B, C, and D, from lowest to highest risk. Classification follows rules based on intended use, invasiveness, duration, active functions, and the consequences of failure. IVDs also use an A-D risk model with criteria related to individual and public-health risk.

A documented classification decision is essential because it determines the Medical Device Marketing Authorization (MDMA) route and the depth of technical, clinical, performance, and quality-system evidence. Reference-market classifications can inform the analysis but should not replace an SFDA-specific assessment.

Authorized representative and establishment licensing

A foreign manufacturer generally appoints a Saudi Authorized Representative with the appropriate SFDA authorization. The representative is the local regulatory contact and supports the MDMA application and lifecycle obligations. Relevant establishments in the supply chain must also hold the licenses required for their activities.

The representation agreement should define access to the technical file, authority communications, change notification, renewal, import coordination, complaints, vigilance, recalls, and registration transfer. These provisions matter commercially because the representative holds operational responsibilities after approval, not just during submission.

MDMA dossier and review

The application commonly includes manufacturer and site details, quality-management-system evidence, intended use, classification rationale, device descriptions, labeling and instructions for use, authorization documents, conformity or reference-market evidence where applicable, risk management, verification and validation, and clinical or performance evidence proportionate to risk. Arabic labeling requirements and data entered in the SFDA system must be consistent with the approved scope.

After authorization, manufacturers and local partners must keep licenses, certificates, product data, labeling, and authorized models current. Complaints, adverse events, field safety corrective actions, and recalls need documented local processes. A change to design, intended use, software, manufacturing site, labeling, or quality system should be assessed before implementation to determine whether SFDA notification or approval is required.

Saudi Arabia pathway and evidence decisions

The Medical Devices Law and implementing regulation require the applicable market authorization, with defined exceptional situations. Do not assume that a historical reference-approval pathway or low-risk listing statement replaces the current technical-file requirements. Keep local representation, establishment licensing and product authorization separate.

Use the official SFDA instructions and related official process guidance for the filing scope. Maintain a controlled record of the chosen route, current evidence, open gaps, responsible parties and authority responses. Separate fees, document preparation, review and applicant work when planning the launch.

For a multi-country program, use the market directory to coordinate evidence reuse while retaining the local applicant, language, registration and postmarket requirements for each destination.